Nile Therapeutics, Inc.

May 31, 2007 - Peter M. Strumph Named CEO of Nile Therapeutics » Read
September 18, 2007 - Nile Therapeutics, Inc. Completes $20 Million Financing and Reverse Merger with SMI Products, Inc. » Read
September 21, 2007 - Nile Therapeutics, Inc. Adds to Executive Management Team » Read
October 2, 2007 - Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum » Read
October 11, 2007 - Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure » Read
October 11, 2007 - Nile Therapeutics Announces Change to Stock Ticker Symbol » Read
October 18, 2007 - Nile Therapeutics Appoints Pedro Granadillo to Board of Directors » Read
October 25, 2007 - Nile Therapeutics to Present at the Rodman & Renshaw 9th Annual Healthcare » Read

January 28, 2008 - Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors » Read
February 5, 2008 - Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference » Read
February 6, 2008 - Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP » Read
February 25, 2008 - Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics » Read
March 13, 2008 - Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results » Read
May 8, 2008 - Jane Moffitt, J.D., LL.M. Named Vice President of Regulatory Affairs of Nile Therapeutics » Read
May 12, 2008 - Nile Therapeutics Announces Move to The NASDAQ Capital Market » Read
May 13, 2008 - Nile Therapeutics to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference » Read
May 15, 2008 - Nile Therapeutics Reports 2008 First Quarter Financial Results » Read
June 18, 2008 - Nile Therapeutics Completes License Agreement for CU-NP, a Rationally Designed Natriuretic Peptide » Read
July 11, 2008 - Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients » Read
July 16, 2008 - Nile Therapeutics to Ring the NASDAQ Stock Market Closing Bell » Read
July 30, 2008 - Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart » Read
August 14, 2008 - Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results » Read
August 27, 2008 - Nile Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference » Read
October 1, 2008 - Nile Therapeutics to Present at the Maxim Group Growth Conference » Read
October 14, 2008 - Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure » Read
November 3, 2008 - Nile Therapeutics to Present at Two Upcoming Investor Conferences » Read
November 13, 2008 - Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results » Read
December 9, 2008 - Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure » Read

January 13, 2009 - Nile Therapeutics to Present at the 27th Annual J.P. Morgan Healthcare Conference » Read
January 20, 2009 - Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program » Read
February 3, 2009 - Nile Therapeutics to Present at the 2009 BIO CEO & Investor Conference » Read
March 9, 2009 - Nile Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results and Announces Conference Call on March 10, 2009 » Read
March 18, 2009 - Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives » Read
March 27, 2009 - Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure » Read
May 14, 2009 - Nile Therapeutics Reports 2009 First Quarter Financial Results » Read
May 15, 2009 - Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA » Read
July 8, 2009 - Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement » Read
July 16, 2009 - Nile Therapeutics, Inc. Completes $3.4 Million Private Placement » Read
August 13, 2009 - Nile Therapeutics Reports 2009 Second Quarter Financial Results » Read
September 14, 2009 - Nile Therapeutics Announces Poster Presentation at 2009 Heart Failure Society of America Annual Meeting » Read
September 25, 2009 - Nile Therapeutics Appoints Frank Litvack, M.D., to Board of Directors » Read
September 29, 2009 - Nile Therapeutics Appoints Arie S. Belldegrun, M.D., to Board of Directors » Read
November 12, 2009 - Nile Therapeutics Reports 2009 Third Quarter Financial Results » Read

February 4, 2010 - Nile Therapeutics to Present at BIO CEO and Investor Conference » Read
March 3, 2010 - Nile Therapeutics Reports 2009 Fourth Quarter and Full Year Financial Results » Read
April 6, 2010 - Nile Therapeutics Announces Proposed Public Offering » Read
April 22, 2010 - Nile Therapeutics Announces Pricing of Public Offering » Read
May 7, 2010 - Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study » Read
May 10, 2010 - Nile Therapeutics Announces Exercise of Over-Allotment Option for Recent Public Offering » Read
May 14, 2010 - Nile Therapeutics Reports 2010 First Quarter Financial Results » Read
June 4, 2010 - Nile Therapeutics Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule » Read
July 6, 2010 - Nile Therapeutics Completes Dosing of Phase II Study » Read
July 22, 2010 - Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors » Read
August 16, 2010 - Nile Therapeutics Reports 2010 Second Quarter Financial Results » Read
October 7, 2010 - Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board » Read
November 2, 2010 - Nile Therapeutics Phase 2 Study of CD-NP in Patients with Acute Decompensated Heart Failure Meets Primary Endpoint, Has Favorable Trends on Renal Function » Read
November 12, 2010 - Nile Therapeutics Reports 2010 Third Quarter Financial Results » Read
November 16, 2010 - Nile Therapeutics to Present at Maxim Group Growth Conference » Read